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An aura of controversy has always accompanied 
the development of biotechnology and its 
extension to a number of scientiic and medical 
domains up to present days. As a matter of fact, 
as highlighted also by other contributors to this 
volume1,2, the way in which biotechnology is 
regulated calls into question the very essence of 
liberal democratic science policy and thus urges 
an analytical effort at clarifying the foundations 
of governance options in this domain and the 
values they embed.
With this objective in mind, one cannot 
fail to acknowledge that stem cell biology 
epitomizes this common trait of controversy 
in biotechnological progress: starting from the 
late Nineties, the stem cell community was 
caught in the midst of a planetary political 
battle over the ethical legitimacy of stem 
cell research, especially as it concerned the 
derivation of pluripotent and multipotent 
stem cells from human embryos and fetuses. 
The latter’s moral status was hotly debated 
and required landmark political and judicial 
decisions that, differently in different countries, 
ixed the limits and the conditions for the use 
of early human conceptuses for scientiic and 
clinical research3. However, the debate about 
the governance of stem cell research did not 
cease to be contentious after the emergence of 
speciic normative arrangements to regulate 
the use of embryos and fetuses. Quite to the 
contrary, while the philosophical debate on the 
moral status of early human life is still open4, 
scientists and commentators raise new concerns 
about the way existing regulations impinge on 
the ability of stem cell science to deliver its 
promised clinical applications.  A great deal 
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of current debates on stem cell research thus 
revolves around the governance of the so-called 
scientiic translation of stem cell research into 
usable regenerative medicine5. The notion of 
translational science designates a phase in the 
development of scientiic innovation (between 
basic research and its clinical application), as 
well as a modality of scientiic inquiry aimed at 
providing the scientiic rationale to include safe 
and effective new treatments into the standard 
of health care. Contrary to what might be 
assumed to be the case, however, the epistemic 
and regulatory foundations of translational 
science are not clearly established: in fact, 
disagreement and even conlict insist on the 
ethical assessment, the scientiic justiication, 
the political regulation and the commercial 
aspects of biotechnological innovation in the 
ield of regenerative medicine, as well as in 
other areas of biomedical innovation. 
This paper sets out to show that different 
and indeed antagonistic models of clinical 
translation are emerging in the realm of cell-
based regenerative medicine embodying rather 
different ontological, epistemic, ethical and 
regulatory assumptions. In this article I will thus 
illustrate two prominent bodies of professional 
guidance issued by two different scientiic 
societies active in the ield of stem cell-based 
regenerative medicine: the International 
Society for Stem Cell Research (ISSCR) and 
the International Cellular Medicine Society 
(ICMS). These guidelines offer strikingly 
diverging accounts of how stem cells should 
be translated into therapies for patients, thus 
demonstrating the existence of disjunctive 
framings of clinical translation. Each scientiic 
society enacts speciic discursive strategies to 
project legitimacy onto their respective framings 
of regenerative medicine: both mobilize – and 
to a good extent, construct – at the same time 
ad hoc epistemic and professional norms to 
corroborate their claims as to how the translation 
of stem cell science into regenerative medicine 
is supposed to take place and to be regulated. In 
this confrontation the co-production of science 
and social order6 comes to be seen in bold relief, 
as evidentiary standards, medical categories, 
regulatory arrangements and professional 
liability become embedded in translational 
models of regenerative medicine. 
In what follows, this paper describes complex 
strategies to attain at the same time professional 
cohesion and public trust in the scientiic 
activities of a given group of scientists. In this 
perspective, looking at the different routes 
towards standardization that are being mobilized 
by professional scientiic societies provides the 
opportunity for a deeper understanding of the 
very constitution of translational options in 
regenerative medicine. 
Regenerative medicine: work in progress
Before devoting our attention to reconstructing 
how the ISSCR and the ICMS imagine stem 
cell-based regenerative medicine and its 
translation from laboratories to clinical wards, 
it is advisable to clarify how the notion of 
regenerative medicine is to be understood. The 
following deinition may thus be useful to this 
aim, as it captures the large semantic latitude of 
regenerative medicine in a relatively condensed 
way:
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« Regenerative medicine is an interdisciplinary 
ield of research and clinical applications focused 
on the repair, replacement or regeneration 
of cells, tissues or organs to resort impaired 
function resulting from any cause, including 
congenital defects, disease, trauma and ageing. 
It uses a combination of several converging 
technological approaches, both existing and 
newly emerging, that moves it beyond traditional 
transplantation and replacement therapies. The 
approaches often stimulate and support the 
body’s own self-healing capacity »7.
Albeit not new, the idea of restoring the 
impaired functioning of bodily structures 
through products of biological origin recently 
re-gained momentum as science proved able 
to experimentally control the proliferative 
and differentiative fate of human cells both 
in vitro and in vivo. Those new manipulative 
abilities tempt biomedical researchers to probe 
how stem cells could be harnessed to restore 
the functionality of diseased human bodies. In 
truth, the rationale for taking this therapeutic 
direction is not entirely original8. Bone marrow 
grafts for patients affected by hematological 
cancer represent the irst stem cell therapy to 
successfully bridge the gap from the bench to the 
patient’s bedside9. Other familiar examples of 
regenerative medicine are blood transfusions and 
organ transplantations: these examples conirm 
that the human body is already being used as 
materia medica in contemporary medicine. 
However, one main difference between these 
early examples of regenerative medicine and 
what stem cells might do in terms of bodily 
regeneration in the imminent future needs to be 
highlighted. Blood and organs are transferred 
from one body to another following relatively 
minor manipulations, apart from those handling 
procedures (like refrigeration for example) that 
are necessary to keep them useable while being 
transported from the donor to another recipient 
body. The current idea of regenerative medicine, 
however, generally means more than this from 
a technical point of view. In regenerative 
medicine, the displacement of human cells from 
one body to another (heterologous treatment) or 
the re-implantation of cells extracted from the 
same patient (autologous treatment), is generally 
mediated by molecular-level manipulations that 
transform a given body “part” into the desired 
kind of entity that the receiving patient needs. 
This manipulation can be both qualitative and 
quantitative: techniques that are typically used 
in molecular biology laboratories can now be 
translated to the clinic to both alter the identity 
of a given set of stem cells (for example by 
directing them towards more differentiated 
phenotypes) or to expand them, thus increasing 
their number up to the amount necessary for 
therapeutic use. Furthermore, in recent years, 
techniques have been developed to reprogram 
fully differentiated cells to a pluripotent state10, 
from which they can subsequently be driven 
to any somatic lineage and, in theory, be 
used for therapy – thus avoiding the ethically 
contentious destruction of human embryos that 
was previously needed to obtain pluripotent 
stem cells11. 
Schematically, there exist three major modes 
of activity that can be exploited in cell-based 
regenerative medicine. Cells injected into a 
patient, whether they come from the same patient 
or from a donor, could provide a therapeutic 
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function by either: secreting trophic factors and 
exerting an immunomodualtory activity12 (e.g. 
reducing localized inlammation); replacing 
a piece of damaged cellular structure with or 
without the support of biomaterials and synthetic 
scaffolds13 (e.g. in chondrocyte-based cartilage 
replacement treatment14); by reconstituting 
in vivo a cellular structure starting from the 
injection of stem cells that have the capacity to 
differentiate in an orchestrated and hierarchical 
fashion (e.g. neural stem cells for treating the 
effects of ischemic stroke15). In all the above cases 
the cells of origin can be stem cells, progenitors 
or differentiated cells (as such, or obtained 
through reprogramming) depending on the 
technical protocol chosen by the research team. 
Arguably, the future of the ield crucially 
depends on the development of safe and effective 
cell therapies and cell products, and thus relies 
as much on technical progress as it relies on the 
emergence of a common governance framework 
that is able to assure an ethically defensible 
and scientiically reliable translation of stem 
cells. The gold standard for the validation of 
biomedical innovation in Western medicine 
is the standardized generation of knowledge 
through clinical trials conducted according 
to the epistemic principles of evidence-based 
medicine16. As a matter of fact, however, stem 
cell translation is a global enterprise featuring 
a number of actors racing to deliver as soon as 
possible their cellular products and therapies to 
the market. In this context, different actors have 
different ideas about how stem cell biology 
should be translated into regenerative medicine. 
Alongside technical uncertainties, regulatory 
gaps and a heterogeneous global legislative 
framework also affect the development of 
regenerative medicine, thus leaving the debate 
open about how public authorities should 
regulate this process, how patients should be 
involved and, inally, how this science should be 
exploited commercially. It is in this scenario that, 
in recent years, stem cell clinics arose offering 
stem cell treatments directly to patients, contrary 
to the advice of large sectors of the scientiic 
community. Stem cell medicine centers are 
active in the US, in Europe and Central America 
as well, but most of these clinics are reported to 
be in Asia (especially in China17). The typology 
of injected cellular products ranges from fetus-
derived cells, to autologous adult stem cells of 
various origin, employed to treat a variety of 
conditions including arthritis, fatigue, Parkinson 
disease, stroke and sometimes cancer. The 
scientiic community has been rather consistent 
in considering those treatments as scientiically 
unproven18, medically unjustiied, and ethically 
unwarranted, but a market of adult stem cell 
therapies nevertheless arose.
Some prominent protagonists of this dispute 
produced guidance documents that demarcate 
the validity of their own respective framings 
of stem cell innovation. In the next section, 
I will reconstruct such effort by reporting 
about alternative understandings of stem cell 
innovation by, respectively, the ISSCR and the 
ICMS. The recent activity of these two scientiic 
societies provides evidence as to the emergence 
of alternative framings of stem cell innovation in 
the ield of regenerative medicine. In what follows 
I will thus reconstruct the ontological, epistemic 
and regulatory commitments that constitute 
their respective order-making strategies.
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Normalizing the boundaries of stem cell 
medicine: the epistemic vigilance of the 
ISSCR
The International Society for Stem Cell Research 
(ISSCR) is a scientiic society established in 
2002 to promote the advancement of stem cell 
research. During the irst ten years of its activity 
the ISSCR has earned international renown for 
the scientiic reputation of its members, who 
are among the major igures of last decade’s 
advancements in the science of stem cells. 
In 2008, as the issue of stem cell clinics was 
gaining headlines in both scientiic and popular 
press, the ISSCR published a set of speciic 
Guidelines for the Clinical Translation of Stem 
Cells19. This document – written by a dedicated 
multidisciplinary task force20 – offers advice 
as to how to attempt scientiically sound and 
ethically defensible stem cell clinical translation. 
At irst, the document establishes a clear-
cut distinction between responsible clinical 
translation – assured by voluntary adherence to 
the guidelines recommendations – and unproven 
commercial stem cell interventions. As a matter 
of fact, one of the main purposes of this body of 
guidance is to reafirm that stem cell therapies 
marketed directly to patients before proper 
clinical validation are scientiically inconsistent 
and morally dubious. As a matter of fact, in 
recent years, patients who exhausted other 
clinical options, or were simply lured by cellular 
medicine advertised through the Internet, have 
spent considerable amounts of money for 
non-validated cell-based interventions, often 
travelling to distant countries to avoid restrictive 
regulatory regimes. The ISSCR considers these 
interventions as possible sources of fraud and 
exploitation as they are not backed by any 
« credible scientiic rationale, transparency, 
oversight, or patient protection »21, as speciied 
by the Guidelines.
To counteract this phenomenon, the ISSCR 
guidance vigorously subscribes to the idea 
that certiied scientiic knowledge cannot be 
obtained but through the cherished procedure 
of peer-reviewing. The latter principle stands 
as a deining pillar in the ediice set up by 
these guidelines. As a consequence, ISSCR’s 
guidelines endorse evidence-based clinical 
trials as the most accredited source of peer-
reviewed knowledge-making in the clinical 
ield and downplay the reliability of procedures 
that bypass or avoid them. According to this 
framing, the clinical translation of stem cells 
should resemble that of synthetic drugs and 
therefore take place through the conventional 
pipeline of knowledge certiication of regular 
clinical trials. In this respect, this framing 
attempts to normalize22 the clinical development 
of regenerative medicine and thus to project 
order onto this emerging ield of biomedical 
innovation. The novelty of stem cell medicine, 
with its epistemic and ethical uncertainties, is 
thus tamed through stipulating which modalities 
of knowledge production and certiication are 
admissible and which are not. The document 
therefore abides to a modality of knowledge 
making that Cambrosio and colleagues aptly 
described as a form of « regulatory objectivity »23. 
Importantly, the ISSCR guidelines acknowledge 
a role of regulatory oversight to bioethics 
committees and, most notably, to governmental 
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agencies like the Food and Drug Administration 
(FDA) in the United States or the European 
Medicines Agency (EMA) in Europe, thus 
coupling the epistemic authority of the scientiic 
community with the regulatory power of the 
State. Further conirmation of these purported 
alliances can be found in the ISSCR Patient 
Handbook on Stem Cell Therapy, also published 
in 2008 and available on the society’s website. 
This document, other than popularizing a few 
basic notions about the biology of stem cells 
and their possible medical promises, warned 
potential patients of stem cell treatments 
to be watchful when approaching stem cell 
clinics, especially if the latter failed to show: 
1) peer-reviewed replicable preclinical studies, 
2) the existence of an Institutional Review 
Board (IRB) or Ethics Review Board (ERB) 
assessing the proposed intervention from an 
ethical standpoint, and 3) the approval of a 
regional or national regulatory agency. In 
addition, the handbook alerted patients to be 
particularly wary of stem cell treatment providers 
when: patient testimony is the only basis for 
eficacy and safety claims, the same cells are 
used to treat a multiplicity of conditions, clear 
documentation is missing as to the source of the 
cells or nature of the treatment, and risks are 
said to be absent. 
The pragmatic standardization of knowledge-
production through clinical trials, the ethical 
oversight by dedicated bioethics committees 
and the regulatory oversight of public 
authorities are thus also construed, respectively, 
as the epistemic, ethical and regulatory 
irewalls to protect patient from fraudulent 
commercialization of unproven treatments. 
ISSCR does not however deny that medical 
innovation can, and indeed does occur also 
outside clinical trials. The guidelines therefore 
advance the notion of “Stem Cell Medical 
Innovation”. This notion closely resembles the 
idea of compassionate use of still not fully proven 
therapies for individual patients, as it demarcates 
the boundary between acceptable administration 
of unproven stem cell therapies to a very small 
number of patients and unacceptable unproven 
stem cell treatments marketed to an indeinite 
amount of patients. Again, rigorous peer-review 
of the scientiic rationale for attempting “Stem 
Cell Medical Innovation” outside the framework 
of clinical trials, and ethical oversight by 
accredited authorities is the deining criterion 
for such modality of clinical innovation.
We can therefore conclude that this framing of 
stem cell translation allows science, bioethics 
and regulatory authorities to build order – 
and thus to exert control – over the early 
development of regenerative medicine. Here, 
stem cell medicine gets normalized through 
assimilating the norms of clinical knowledge-
making: for this reason the translational model 
advanced by the ISSCR has been rightly dubbed 
a « cells-as-drugs »23 approach. In this framing, 
regenerative medicine becomes at the same 
time entrenched in a narrative of ethical and 
regulatory oversights featuring the scientiic 
community, professional bioethics and state 
agencies as exerting epistemic vigilance on the 
translation of stem cell science into medical 
applications.
In the coming section, I will analyze a 
substantially different approach to stem cell 
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translation, proposed by the International 
Cellular Medicine Society in roughly the same 
years as the ISSCR.
ICMS: standard setting for the naturalization 
of stem cell medicine 
The International Cellular Medicine Society is 
a non-proit international medical association 
that brings together physicians and researchers 
from thirty-ive countries with a shared interest 
in advancing « point-of-care cell-based thera-
pies »25 by means of autologous stem cell 
transplants. The ICMS also describes itself 
in its website as a « standards organization 
that produced the irst ever set of guidelines 
for the practice of cell-based medicine »26. 
Those guidelines enact a completely different 
translational model than ISSCR’s cells-as-drugs 
framing, one that is actually backed by overt 
adversarial intentions – as testiied by the content 
of an open letter of ICMS’ director available on 
the society’s website and reading as follows:
« The ICMS will not stand by to allow the ISSCR 
or any other entrenched interest to discredit all 
stem cell therapies. In order to halt these vicious 
attacks, we believe that a set of international 
standards are needed to ensure patient safety 
and to help this ield develop in the direction of 
responsible medical practice »27.
Guidance documents – adopted by the ICMS 
between 2009 and 2010 – focus exclusively 
on autologous adult stem cell transplants of 
minimally manipulated cells. The latter are 
conceptualized as being part of the patient’s 
body and « represent the ability of the body 
to heal itself »28. In this sense, the therapeutic 
essence of stem cells is thus naturalized and, at 
the same time, it comes to constitute the basis 
for a right of patients to use a healing material 
that is their own. The naturalization of stem 
cell therapy, as opposed to the normalization 
of clinical translation promoted by the ISSCR, 
amounts at an ontological categorization of 
stem cells as natural parts of patient’s body. This 
ontological move implies an ad hoc epistemic 
and regulatory architecture for knowledge 
certiication – one that departs starkly from the 
standards of regulatory knowledge supported by 
the ISSCR. 
The architrave of the guidance set forth by 
ICMS is its support of « legitimate medical 
innovation outside the context of clinical 
trials »29 based on two preliminary assumptions: 
irst, the explicit endorsement of therapeutic 
freedom as formulated in claims afirming 
that « an informed patient has the right to 
access innovative therapies », or that « [i]n
consultation with a qualiied physician, 
a patient must be empowered to make an 
informed healthcare decision »30; and second, 
the idea that « autologous adult stem cells 
is the practice of medicine and, as such, is 
subject to the laws and regulations that cover 
the practice of medicine »31. The patient-doctor 
relationship and the relationship of patients 
with their bodily material are thus framed as 
exclusive ones, whereby undue regulatory 
interference, for example by State agencies or 
expert communities, is in principle unjustiied.
The activity of regulatory agencies and of the 
scientiic community against the practice of 
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unproven stem cell medicine is perceived as 
bearing diverging ends with respect to the 
therapeutic rights of patients and to the exercise 
of the medical profession. The quotes above 
instantiate the refusal of what we might want 
to call regulatory paternalism. Paternalism, in 
general, means interference with a person’s will 
justiied by the assumption that this interference 
will beneit that person in some way or prevent 
harm for occurring to her. There are numerous 
contexts where paternalistic intervention may 
occur, and numerous versions of paternalistic 
interventions32, but health care is deinitely one 
of the most prominent areas where paternalism 
is discussed. Typically, medical paternalism 
refers to physicians withholding important 
information about a patient, allegedly, to protect 
that patients from harm that that information 
may provoke. But in our case, the ICMS clearly 
constructs regulatory and epistemic norms 
regulating stem cell medicine as a form of 
undue interference with people’s therapeutic 
freedom, and indeed a paternalistic one, given 
the motivation for such arrangements is the 
protection of inal users.  In this instance, 
paternalist allegations are not directed to the 
practicing doctor, but to biomedical researchers 
and governmental agencies who impose their 
views on how innovative practices should be 
traded against the will of patients to access the 
kind of therapy they prefer.
One may want to argue that such a 
conceptualization of therapeutic rights as 
opposed to regulatory paternalism is typical of 
health care systems where, like it is the case 
in the US, « physicians often work in fee-for-
service settings, and they become allies with 
their patients in a consumerist demand for more 
patient autonomy in purchasing services »33. 
As a matter of fact however, unproven stem 
cell therapies where commercialized also in 
Europe34 and in particular in Italy – a country 
that enjoys a national health care service 
covering all citizens almost for free – under 
controversial interpretations of the notion of 
compassionate use and of the hospital exemption 
rule that regulates it35. This testiies that the 
naturalization narrative, with all its load of 
ethical and regulatory assumptions, can spread 
across different models of health care and that 
it is probably sustained as much by commercial 
attitudes as by patients’ eagerness to access new 
therapies. 
Risk and the re-making of regulatory 
ontologies by ICMS
Constructing stem cell medicine outside 
conventional modalities of knowledge 
production requires a complex exercise in 
remaking medical and regulatory ontologies. 
This effort on the part of the ICMS relies 
primarily on the introduction of a grading system 
for stem cell treatments and on the deinition of 
ready-to-use risk assessment criteria. 
Through to the ICMS guidelines, attempted 
cell-based procedures need to be assessed 
according to a “clinical staging” classiication36. 
In a not too hidden effort at mimicking the 
epistemic structure of stepwise clinical trials, 
clinical staging includes a hierarchy of steps 
that treatments must pass in order to be used 
in clinical practice. According to this schema, 
stem cell procedures are graded primarily as to 
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the number of patients they were used for and 
the extent of post-use monitoring that followed 
the treatment. For example, cells that have never 
been used in humans but were used in several 
animal models without adverse reactions are 
called Early Investigational Cell Lines. These 
can be used on a small number of patients (ive 
to ten) and should be monitored for at least six 
months for adverse reactions. If no signiicant 
complication is reported, the procedure can 
pass to the next step of the grading scale, 
meaning those cells can be considered Late 
Investigational Cell Lines, and can be used 
on a bigger group of patients (twenty to ifty). 
Fulilling the requirements of previous stages is 
a prerequisite to move up to the next stage of 
the grading, all the way up to Early and Late 
Clinical Cell Lines (between one and three-
hundred patients followed up for six months) 
and inally to the highest, unrestricted status 
of Clinical Grade Cell Lines. The history of a 
treatment’s previous uses (and thus the evidence 
for its current grading) is reported in a treatment 
registry administered by the ICMS. It is the 
Registry’s scientiic committee – composed 
of ICMS members – that then determines the 
grading of deposited lines according to the 
above-described criteria. Adhering to this 
voluntary system, stem cell doctors accept 
ICMS as a source of scientiic accreditation 
and patients are allegedly assured of the safety 
of novel cell-based procedures. The registry is 
therefore a tool (epistemic and regulatory) by 
means of which ICMS alone uptakes all the 
burden of certifying the safety of stem cell re-
implantation procedures. Contrary to the ISSCR 
framing, here the FDA and similar agencies 
are not considered by the ICMS as legitimate 
partners in stem cell innovation. Moreover, as 
to the relationship between doctors and patients, 
it is not conceptualized under conventional 
bioethical categories. 
A point to mention here is that, being clinical 
staging about autologous stem cells, it is not 
possible to understand the expression ‘cell line’ 
in terms of direct lineage with a clonal ancestry. 
Since in this modality every patient receives 
an injection of newly established ex vivo cell 
batches, it is indeed inappropriate to speak 
of cell lines37. Moreover, the clinical staging 
system does not mention any speciic criterion of 
demarcation between the controlled production 
of generalizable medical knowledge (i.e., the 
aim of proper clinical trials) and the clinical use 
of stem cells in medical practice: knowledge is 
produced – if at all – by observing the effects 
of clinical practice, and clinical practice is the 
activity from which data are collected to form 
the basis of knowledge and risk assessment 
claims38. 
This strategy is clearly alternative to ISSCR’s 
framing, but it also relies on further classiicatory 
elements in the ICMS guidelines. This document 
lays down a « risk stratiication system for tissue 
translation »: with the aim of framing autologous 
stem cell therapy as bearing only minimal 
risks, the guidelines attempt an unprecedented 
classiication of human tissue types. The 
proposed classiication lumps together different 
tissues so that, for instance, muscle, tendon, 
cartilage, bone, ligament and intervertebral 
disc all make up the same group (called 
“mesodermal orthopedic tissue”). The idea 
behind this classiicatory effort is to link bodily 
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sites to ready-made risk assessment criteria. So, 
for instance, cells extracted from and re-injected 
in the same tissue group bear only minimal risk, 
whereas attempting to transplant a cell type that 
belongs to a group into a bodily site that belongs 
to another implies more than minimal risks. Far 
from relecting naturally occurring categories, 
this classiication is mobilized to accommodate 
favorable risk proiles for practiced stem cell 
procedures. Anatomical categories are thus 
rearranged in a way that its assumptions about 
the safety of practicing stem cell therapists. Risk 
assessment here is, again, naturalized according 
to a physiological classiication, in an effort to 
project order onto the medical practice of cell 
therapy. This whole classiicatory exercise thus 
relies on the mutually reinforcing construction 
of unconventional criteria of knowledge-making 
and ready-to-use risk assessment parameters: 
in this way, the medical representation of the 
human body gets remade to become liable to 
stem cell medicine. By the same token, criteria 
of clinical risk are spelled out according to such 
new ontologies, so that the practice of stem cell 
medicine can be constructed outside the epistemic 
and regulatory territory of conventional forms 
of knowledge-making and risk assessment. This 
framing constructs the patient as entitled to 
pursue her therapeutic choices with her “own” 
cells, following the advice of the doctor she 
chose, without the interference of regulatory 
agencies. Again, as in the previous case, ICMS’ 
guidance relies on a pragmatic repertoire of 
practices and classiications to make a given 
version of cell medicine possible, namely in the 
form of a free commercial transaction between 


























Table 1. Main features of disjunctive framings of stem cell translation. 
CCTs: controlled clinical trials; EBM: evidence-based medicine. 
* a dedicated legal regime is not demanded, but neither excluded a priori by the ISSCR. 
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Conclusion
In this paper I showed that the constitution of 
human bodily elements as a new kind of materia 
medica is presently taking shape as a scientiic 
controversy. Especially in this early translational 
phase, there appears to be multiple models of 
regenerative medicine competing to establish 
their respective framings as the benchmark 
for the future development of the ield: the 
guidelines issued by scientiic stakeholders 
mobilize radically different imaginaries39 of the 
present and the future of regenerative medicine 
(see Table 1). Those framings are disjunctively 
organized around contrasting epistemic and 
ontological assumptions. On the epistemic side, 
the two scientiic societies embrace two different 
models of knowledge making and validation. 
On the one hand, the ISSCR espouses a model 
of normalization for the scientiic development 
of stem cell medicine – one that projects 
existing standardized modalities of knowledge 
production on novel therapeutic entities like 
stem cells. On the contrary, the ICMS refuses 
this epistemic norms and elaborates ad hoc 
criteria of clinical validity for the practice 
of autologous stem cell medicine. From an 
ontological point of view, the ISSCR deines 
cells as drugs whereas the ICMS constructs stem 
cells as bodily elements thus naturalizing their 
therapeutic potential as well as the criteria that 
allow their safety evaluation. Those transactions 
reveal that the development of a new therapeutic 
approach requires conspicuous efforts of 
boundary construction between different 
epistemic commitments and, indeed, the 
deinition of a speciic ontological framework 
for the new medical entities. 
As a matter of fact those epistemic and 
ontological constructions determine the 
respective regulatory outlook of the two societies. 
From a regulatory standpoint, ISSCR suggests 
an epistemic alignment between scientists 
developing stem cell therapies, IRBs and ERBs 
and regulatory oversight agencies, whereas the 
ICMS contrasts this form of oversight as an 
instance of regulatory paternalism. 
The ISSCR sees the patient as an epistemically 
vulnerable party that the scientiic community 
has the duty to inform, and possibly warn 
about unproven therapeutic options. In the 
naturalized framing, instead, cells are conceived 
as a patient’s body parts thus enabling their use 
on the basis of a natural entitlement as well as 
of an individual right of therapeutic freedom. 
Given these premises and given the prevalent 
commercial character of the kind of treatment 
offered to patients under this framing in favorable 
jurisdictions, the therapeutic encounter acquires 
here the character of a market transaction 
between providers and consumer of health-
related services. However, this consumerist 
attitude, as I said, is also fed by a growing 
impatience on the side of consumers to access 
innovative therapies as soon as possible. 
The translational models presented in this paper 
testify that the governance of biotechnology 
relies on standardization and classiicatory 
practices attempting to bring order around the 
unsettling presence of new biotechnological 
artifacts40. More speciically, our analysis 
showed that the discursive and pragmatic 
articulation of a space of action – for both 
practitioners and patients – is necessary to 
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make a given framing of regenerative medicine 
possible. To the extent that regenerative 
medicine constructs body parts as medicaments, 
contentious epistemic and regulatory practices 
are called into question in order to realize this 
far from obvious ontological leap. This results 
in the presence of contrasting interpretations 
about how stem cells should be translated to the 
clinic – one drawing on normalization and the 
other on naturalization as discursive-pragmatic 
governance resources.
Indeed, regenerative medicine will keep on 
evolving in the next future as new scientiic 
knowledge will accumulate and new clinical 
practices will be experimented. Arguably, 
controversy will occur as actors try to build 
professional cohesion and feed public trust in 
their scientiic activities. As a consequence, 
following the trajectory of these translational 
models as they are proposed, contested, defeated 
or supported by scientiic actors and regulatory 
authorities will be key to a critical appraisal 
of the regulatory regime that is stabilizing this 
bursting domain of scientiic innovation.
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Transposer les cellules souches en clinique : sociétés 
savantes et structuration de la médecine régénérative
Dans cet article, l’auteur présentera deux corpus de 
lignes directrices professionnelles établies par deux 
sociétés savantes œuvrant dans le domaine de la 
médecine régénérative utilisant des cellules souches : 
la « Société internationale pour la recherche sur les 
cellules souches » (ISSCR) et la « Société interna-
tionale de médecine cellulaire » (ICMS). Ces lignes 
directrices présentent des points de vue divergents 
sur la façon dont les cellules souches devraient être 
utilisées en thérapie pour les patients. Elles démontrent 
l’existence de postures alternatives pour l’encadrement 
de l’utilisation clinique de ces cellules en s’appuyant 
sur des hypothèses ontologiques, épistémologiques, 
éthiques et réglementaires différentes. Ces deux in-
terprétations radicalement opposées sur la façon dont 
les cellules souches devraient être transposées pour des 
applications cliniques, s’ancrent respectivement sur 
des postures narratives soit de normalisation soit de 
naturalisation. Ces dernières sont envisagées comme 
des ressources pragmatiques- discursives permettant 
d’articuler le présent et l’avenir de la médecine régé-
nérative.
S’intéresser aux différentes voies de normalisation 
de la médecine régénérative constitue une véritable 
opportunité pour une compréhension approfondie de 
la constitution même des options du passage à l’utili-
sation clinique des cellules souches. En effet, dans le 
futur, la médecine régénérative va continuer à évoluer 
puisque de nouvelles connaissances scientiiques s’ac-
cumuleront et de nouvelles pratiques cliniques seront 
expérimentées. On peut même soutenir que la contro-
verse sera plus importante dans la mesure où les acteurs 
essaient de construire la cohésion professionnelle et 
de nourrir la coniance du public dans leurs activités 
scientiiques. En conséquence, suivre la trajectoire de 
ces modèles translationnels tels qu’ils sont proposés, 
contestés, rejetés ou soutenus par les acteurs scienti-
iques et les autorités réglementaires sera fondamental 
pour permettre une évaluation critique des régimes 
d’encadrement qui stabiliseront ce domaine émergent 
de l’innovation scientiique.
Abstract
In this article I will illustrate two prominent bodies of 
professional guidance issued by two different scientiic 
societies active in the ield of stem cell-based regen-
erative medicine: the International Society for Stem 
Cell Research (ISSCR) and the International Cellular 
Medicine Society (ICMS). These guidelines offer strik-
ingly diverging accounts of how stem cells should be 
translated into therapies for patients, thus demonstrat-
ing the existence of alternative framings of clinical 
translation relying on diverging ontological, epistemic, 
ethical and regulatory assumptions. These two radically 
contrasting interpretations of how stem cells should be 
translated into clinical applications draw, respectively, 
on a normalization and on a naturalization narrative as 
discursive-pragmatic resources to articulate the present 
and the future of regenerative medicine.
Looking at the different routes towards 
standardization of regenerative medicine provides 
a timely opportunity for a deeper understanding of 
the very constitution of translational options. Indeed, 
regenerative medicine will keep on evolving in the next 
future as new scientiic knowledge will accumulate 
and new clinical practices will be experimented. 
Arguably, more controversy will occur as actors try 
to build professional cohesion and feed public trust in 
their scientiic activities. As a consequence, following 
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the trajectory of these translational models as they 
are proposed, contested, defeated or supported by 
scientiic actors and regulatory authorities will be key 
to a critical appraisal of the regulatory regimesthat 
is stabilizing this bursting domain of scientiic 
innovation.
